Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.68
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Medicus Pharma Ltd. is a clinical-stage biotech company focused on accelerating the development of novel therapeutic assets. Their lead subsidiary, SkinJect Inc., is developing a non-invasive treatment for basal cell carcinoma using a dissolvable microneedle patch to deliver chemotherapeutic agents directly to tumor cells.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Data is available to registered users only
